Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 20, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,491.631 pence per share.
- Transaction Date: April 20, 2007.
Material Changes
Following the repurchase, the Company's Treasury shareholding increased to 288,342,678 shares. The total number of shares in issue (excluding Treasury shares) stands at 5,728,317,686, which represents the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,728,317,686) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (288,342,678) for accurate fully diluted share count calculations.
- Note that this filing is a transactional report and does not contain operational or financial performance data for the period.